Laughter as Medicine
Is laughter good medicine? These breast cancer survivors/thrivers say: Yes!
Systemic Racism and MBC in Clinical Trials
Jumping hurdles to get the treatments you want is the reality for people living with MBC. Add systemic racism into the healthcare mix and it’s clear that more needs to happen, and soon, to create equity and greater diversity in one of the most important tools in the MBC toolbox: clinical trials. In this episode, we check in with Stephanie Walker, who led the BECOME project and spearheads the Black Wo(Men) Speak Symposium, patient advocate and clinical trial participant Rev. Dr. Tawana Davis, and Patient Navigator Valarie Worthy. How does systemic racism affect what Black patients learn about MBC clinical trials? And how can those who need it most break down barriers to the best care?
ASCO 2022: When The Dust Settles, What Are My Treatment Options For ER+/HER2- MBC?
Welcome to the second part of our post–2022-ASCO analysis of the state of affairs in the HR-positive MBC. It was not so long ago that our only options were single-agent endocrine therapy and systemic chemo. We have come a long way over the last couple of decades. Today we are asking Drs. Stephanie Graff, Sara Hurvitz, and Kevin Kalinsky to talk about how they make decisions in the clinic in selecting and sequencing treatments, specifically CDK4/6 inhibitors and the newly approved targeted therapies.
Caregivers: We Can’t Do This Without You!
Celebrate OMBCL’s 100th episode and National Family Caregiver Month by listening to our candid conversations with three committed and courageous caregivers.
MBC101: The HER2-Low Show
The DESTINY-Breast04 trial at ASCO 2022 introduced many people to the term “HER2-low.” But how do you know if you’re HER2-low? In this episode, with the help a breast pathologist and a clinical oncologist we dive into this subtype and what it means to us.